title: Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
abstract: OBJECTIVE
  Circulating tumour cells (CTCs) may be prognostic for biochemical recurrence-free survival (bRFS) in patients with locally advanced high-risk prostate cancer (LAPC) undergoing neoadjuvant chemohormonal therapy (NCHT) and radical prostatectomy (RP).
  
  
  METHODS
  CTCs were detected before and after NCHT, after RP and at follow-up using the CellSearch™-System for 59 blood samples (20 ml) from patients with LAPC (n=15) and, additionally, for 15 control samples.
  
  
  RESULTS
  The median 5-year progression risk was 90%. CTCs (≥1/20 ml) were detected in 53.3% of patients, with a detection rate of 18.6% in sample-adjusted analysis. CTCs were detected at baseline in 20% of patients with LAPC and 6.7% of controls (p=0.6). CTC findings displayed no association with clinicopathological characteristics. The median bRFS of CTC-negative vs. CTC-positive patients was 43.7 (95% confidence interval not reached) vs. 29.2 months (95% confidence interval=26.8-60.6 months), without statistical significance (p=0.76).
  
  
  CONCLUSIONS
  During NCHT and RP, longitudinal CTC presence seems to some extent stochastic, although patients with persistant CTCs post-RP developed biochemical recurrence. No significant association with clinicopathological characteristics or bRFS was observed in patients with LAPC, despite a trend for reduced bRFS in patients with detectable CTCs.
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany mark.thalgott@lrz.tum.de.
authors.forename: Mark
authors.initials: M
authors.lastname: Thalgott
authors.affiliation: Department of Gynaecology and Obstetrics, Ludwig Maximilian University, Munich, Germany.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Rack
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Horn
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Matthias M
authors.initials: MM
authors.lastname: Heck
authors.affiliation: Department of Radiology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Eiber
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Hubert
authors.initials: H
authors.lastname: Kübler
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Margitta
authors.initials: M
authors.lastname: Retz
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Jürgen E
authors.initials: JE
authors.lastname: Gschwend
authors.affiliation: Department of Gynaecology and Obstetrics, Ludwig Maximilian University, Munich, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Andergassen
authors.affiliation: Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
authors.forename: Roman
authors.initials: R
authors.lastname: Nawroth
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000401:mortality*; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011379:Prognosis; D011446:Prospective Studies; D011468:Prostatectomy / Q000401:mortality*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D012307:Risk Factors; D015996:Survival Rate
keywords: Biomarkers; CTCs; circulating tumor cells; molecular marker; prostate cancer